The Transparency Committee asked Novartis to carry out a follow-up study on patients treated with EXJADE® specialty. To answer that request, Novartis asked RCTs to set up a multicentre observational study on patients treated with EXJADE® and presenting with hemosiderosis secondary to repeated transfusions (patients suffering from major beta thalassemia, sickle cell anemia, myelodysplastic syndrome or rare anemia), in mainland France, followed-up for two years: the ESCAPADE study.
That study was satisfactorily completed and despite scarcity, 239 patients were included which enabled Novartis provide Health Authorities the requested data (EXJADE_PIC_RI_Avis 3_CT11042).
Publication with Alain BALEYDIER – RCTs as author.